News
How to differentiate between the terms antimicrobial and antibiotic?
At HIFAS Biologics, we understand that the fight against microbial resistance can be confusing due to the variety of technical terms used. Two frequently confused terms are antimicrobial and antibiotic. Although both relate to the treatment of infections, they have…
Penicillin: a turning point for global health
Imagine living in a world without antibiotics and effective treatments for infections. Before the discovery of penicillin in 1928, this was the harsh reality facing humanity. Infant Mortality and Infectious Diseases Before penicillin, bacterial infections were often a death sentence.…
Louis Pasteur, a key player in the fight against infectious diseases
Louis Pasteur, a 19th century French chemist and biologist, challenged the prevailing scientific beliefs of his time and set a turning point in the conceptualization of medicine and the treatment of infectious diseases. Until the mid-19th century, the theory of…
Innovation for antimicrobial resistance: the HIFAS Biologics approach
The fungal world is an inexhaustible source of innovation for the early discovery of targeted drugs against multidrug-resistant bacterial strains. Our approach at HIFAS Biologics is based on the exploration of fungi and their ability to produce bioactive compounds with…
“Hyphae” in HIFAS Biologics, much more than a name
At HIFAS Biologics we have a clear mission and a very specific goal: to combat microbial drug resistance by researching and developing new antibiotics from fungi. But have you ever wondered what our company name means? Beyond being a simple…
AI: an ally in the fight against antibiotic resistance
AI has been on everyone’s lips for a few years now. And, unsurprisingly, this technology that promises to revolutionize the world with its capacity for iterative improvement has also reached the microbial control sector: an article published less than two…
WHO priority pathogens list 2024 published
The World Health Organization’s (WHO) list of priority pathogens has been published! Just a few weeks ago, the World Health Organization published the “Bacterial Priority Pathogens List 2024”. This highly significant document for the microbial control sector identifies the key…
Key terms in the fight against microbial resistance: Germ vs Pathogen
Have you ever had doubts when using different terms in the fight against microbial resistance? Do you know what is the clear difference between germ and pathogen? Don’t worry! At HIFAS Biologics, we help you to put an end to…
The medicinal potential of endolytic fungi in bioactive mushroom metabolites
The journal Fungi Bioactive Metabolites has recently published research highlighting the therapeutic potential of endolytic fungi. In this study, 108 different species of these fungi were analysed, revealing their unique bioactivities and therapeutic attributes. But what are endolytic fungi? Endolytic…
Our strategy to combat microbial resistance: fungus-driven innovation
The fungal world represents an invaluable source of innovation for early drug discovery targeting multi-resistant bacterial strains. That is our philosophy at HIFAS Biologics. Therefore, our strategy is entirely focused on the research and development of new antibiotics and is…
HIFAS Biologics finalist of the INNOVATE4TOMORROW programme
At HIFAS Biologics we are celebrating! We are very pleased to announce that HIFAS Biologics has been selected as one of the finalists in the INNOVATE4TOMORROW programme, organised by Ayming. This flagship industry programme aims to recognise and reward innovative…
HIFAS Biologics participates in the Galicia Biodays 2024
Although we are back, at HIFAS Biologics we are still excited about what we experienced last week at Galicia Biodays 2024. Our team travelled to the Mar de Vigo Auditorium, in the heart of the Olívica City, on 12 and…